<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702156</url>
  </required_header>
  <id_info>
    <org_study_id>RN05CA013</org_study_id>
    <nct_id>NCT00702156</nct_id>
  </id_info>
  <brief_title>Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Cardioselective Beta-Blockade Using Bisoprolol in Patients With Chronic Heart Failure (CHF) and Coexistent Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) With or Without Significant Reversibility.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal research objectives are to demonstrate cardioselective beta-blockade using
      bisoprolol is not inferior to placebo with regard to pulmonary function and improves quality
      of life in patients with heart failure and coexistent moderate or severe chronic obstructive
      pulmonary disease with or without significant reversibility. Patients will be followed up for
      4 months during which bisoprolol will be up-titrated to the maximum clinically tolerated
      dose. Health status will be assessed using a generic and two disease specific questionnaires,
      and pulmonary function by spirometry, body box plethysmography, and cardiopulmonary exercise
      testing.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate patient recruitment
  </why_stopped>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume 1 second (FEV1)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life: Minnesota Living with Heart Failure, SF-36</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Class</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Heart Failure</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bisoprolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical appearance matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol</intervention_name>
    <description>Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Bisoprolol Fumarate</other_name>
    <other_name>Brand name: Cardicor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptomatic NYHA II or III chronic heart failure

          -  left ventricular systolic dysfunction

          -  moderate or severe chronic obstructive pulmonary disease

          -  with or without significant reversibility

        Exclusion Criteria:

          -  beta−blocker contraindications

          -  non−dihydropyridine (diltiazem / verapamil) calcium channel blockers

          -  recent coronary percutaneous intervention or coronary artery bypass graft surgery

          -  haemodynamically significant valvular disease or hypertrophic cardiomyopathy.

          -  active myocarditis or pericarditis.

          -  recent cerebrovascular accident or transient ischaemic attack

          -  serious concurrent systemic disease, such as malignancy, resulting in likely reduced
             life expectancy

          -  pregnancy, childbearing potential with inadequate contraception, breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel M Hawkins, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Greater Glasgow and Clyde</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis G Dunn, MBChB MD</last_name>
    <role>Study Chair</role>
    <affiliation>NHS Greater Glasgow and Clyde</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Carter, BSc MSc PHD</last_name>
    <role>Study Director</role>
    <affiliation>NHS Greater Glasgow and Clyde</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George W Chalmers, MBChB MD</last_name>
    <role>Study Director</role>
    <affiliation>NHS Greater Glasgow and Clyde</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiopulmonary Transplant Unit Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <last_update_submitted>September 2, 2008</last_update_submitted>
  <last_update_submitted_qc>September 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Nathaniel Hawkins</name_title>
    <organization>Glasgow Royal Infirmary</organization>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Beta-blockers</keyword>
  <keyword>Pulmonary Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

